Foley Mark J
SEC insider (Form 3/4/5 filer). CIK 0001529196. Director at GLAUKOS Corp (GKOS) and 1 other issuer. 15 reported Form 4/5 transactions since Sep 2024; latest on May 28, 2026. Located in ALISO VIEJO, CA.
Companies Foley Mark J has filed insider reports for
- GLAUKOS Corp (GKOS): Director
- Revance Therapeutics, Inc. (RVNC): Director, Officer, CEO
Foley Mark J
CIK: 0001529196
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- May 28, 2026GKOS
GLAUKOS Corp
AwardDirectStock Option (Right to Buy)
3K shares- - May 28, 2026GKOS
GLAUKOS Corp
AwardDirect1.9K shares- - Jan 2, 2026GKOS
GLAUKOS Corp
AwardDirect1.2K shares- - May 29, 2025GKOS
GLAUKOS Corp
AwardDirect2.1K shares- - Feb 26, 2025GKOS
GLAUKOS Corp
ExerciseDirect25K shares at avg. $32.00$800K - Feb 26, 2025GKOS
GLAUKOS Corp
SaleDirect20.7K shares at avg. $120.72$2.5M - Feb 26, 2025GKOS
GLAUKOS Corp
ExerciseDirect15K shares at avg. $24.69$370K - Feb 6, 2025RVNC
Revance Therapeutics, Inc.
AwardDirect84.7K shares- - Feb 6, 2025RVNC
Revance Therapeutics, Inc.
DispositionDirect84.7K shares- - Feb 6, 2025RVNC
Revance Therapeutics, Inc.
DispositionDirect27.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 28, 2026 |  GKOS GLAUKOS Corp | Award Stock Option (Right to Buy) | 2,987 | - | - | Direct |
| May 28, 2026 | GKOS GLAUKOS Corp | Award | 1,878 | - | $0 | Direct |
| Jan 2, 2026 | GKOS GLAUKOS Corp | Award | 1,168 | - | $0 | Direct |
| May 29, 2025 | GKOS GLAUKOS Corp | Award | 2,108 | - | - | Direct |
| Feb 26, 2025 | GKOS GLAUKOS Corp | Exercise | 25,000 | $32.00 | $800,000 | Direct |
| Feb 26, 2025 | GKOS GLAUKOS Corp | Sale | 20,687 | $120.72 | $2,497,335 | Direct |
| Feb 26, 2025 | GKOS GLAUKOS Corp | Exercise | 15,000 | $24.69 | $370,350 | Direct |
| Feb 6, 2025 |  RVNC Revance Therapeutics, Inc. | Award | 84,686 | - | - | Direct |
| Feb 6, 2025 | RVNC Revance Therapeutics, Inc. | Disposition | 84,686 | - | - | Direct |
| Feb 6, 2025 | RVNC Revance Therapeutics, Inc. | Disposition | 27,933 | - | - | Direct |
1-10 of 15 transactions